I continue to be baffled and frustrated by CPHD's pricing of their products given that they are still not profitable after all these years and they have great, in demand products. They recently announced another quarterly loss, this time at -$16.7 million. I can understand pricing products low for a short time to gain market entry or increase market share but this has been going on for years now - and this for the claimed leading DNA diagnostic technology.
The latest 'fumble' is their new Omni diagnostic tool priced at $2,985 when their lesser competition has a tool selling for $5,000. Why not price the Omni at $4,000;still beat the competition and bring in some more, much needed revenues?
I recall a few years back, several of us discussing here CPHD's cut rate pricing on cartridges needed in third world countries. My recollection was that a normally priced cartridge at $34 was being sold for $9, with some charity groups subsidizing the price and increasing it to $17 to CPHD; still 50% of the normal retail price.
Charity is good, etc etc, but when you are far from being profitable year after year, I question their strategy. And it is us shareholders that are paying the price. CPHD management is still getting their salaries, bonuses and stock options.
The Gates Foundation was created because Bill Gates created and marketed a great product FOR A PROFIT. Microsoft and the Gates Foundation would likely not be here today with CPHD's concept of business and charity. Bishop - you got the cart before the horse!